2023
Living donor liver transplant candidate and donor selection and engagement: Meeting report from the living donor liver transplant consensus conference
Jesse M, Jackson W, Liapakis A, Ganesh S, Humar A, Goldaracena N, Levitsky J, Mulligan D, Pomfret E, Ladner D, Roberts J, Mavis A, Thiessen C, Trotter J, Winder G, Griesemer A, Pillai A, Kumar V, Verna E, Rudow D, Han H, Group T. Living donor liver transplant candidate and donor selection and engagement: Meeting report from the living donor liver transplant consensus conference. Clinical Transplantation 2023, 37: e14954. PMID: 36892182, DOI: 10.1111/ctr.14954.Peer-Reviewed Original ResearchMeSH KeywordsConsensusDonor SelectionHumansLiver TransplantationLiving DonorsTissue and Organ ProcurementUnited StatesConceptsDonor selectionConsensus conferenceDeceased donor organ shortageDonor liver transplantationLiver transplant candidatesDonor organ shortageLiver transplantationTransplant candidatesWaitlist mortalityExcellent outcomesLDLT candidatesOrgan shortageDonation outcomesLack of standardizationAmerican SocietyTransplantationDelphi approachBroad implementationMeeting reportOutcomesCandidate indicationsReportLDLTPatientsBroad uptake
2021
American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease
Fix OK, Blumberg EA, Chang K, Chu J, Chung RT, Goacher EK, Hameed B, Kaul DR, Kulik LM, Kwok RM, McGuire BM, Mulligan DC, Price JC, Reau NS, Reddy KR, Reynolds A, Rosen HR, Russo MW, Schilsky ML, Verna EC, Ward JW, Fontana RJ, Group F. American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease. Hepatology 2021, 74: 1049-1064. PMID: 33577086, PMCID: PMC8014184, DOI: 10.1002/hep.31751.Peer-Reviewed Original ResearchConceptsMRNA COVID-19 vaccineCOVID-19 vaccineChronic liver diseaseLiver diseaseModerna mRNA COVID-19 vaccinesCoronavirus disease 2019 (COVID-19) infectionExpert panel consensus statementPrevious drug reactionsAdvanced liver diseaseLiver transplant recipientsAvailable COVID-19 vaccinesDisease 2019 infectionSevere hypersensitivity reactionsLocal site reactionsCare of patientsClinical trial participantsHealth care providersLT recipientsTransplant recipientsAdult patientsImmunosuppressed patientsSystemic reactionsHypersensitivity reactionsSite reactionsVaccine efficacyChanges in Use of Left Ventricular Assist Devices as Bridge to Transplantation With New Heart Allocation Policy
Mullan CW, Chouairi F, Sen S, Mori M, Clark KAA, Reinhardt SW, Miller PE, Fuery MA, Jacoby D, Maulion C, Anwer M, Geirsson A, Mulligan D, Formica R, Rogers JG, Desai NR, Ahmad T. Changes in Use of Left Ventricular Assist Devices as Bridge to Transplantation With New Heart Allocation Policy. JACC Heart Failure 2021, 9: 420-429. PMID: 33714748, DOI: 10.1016/j.jchf.2021.01.010.Peer-Reviewed Original ResearchConceptsDonor heart allocation systemNumber of patientsHeart allocation systemVentricular assist deviceWaitlist survivalAssist deviceNew heart allocation policyLeft ventricular assist deviceAllocation system changePost-transplant mortalityOrgan Sharing databaseOutcomes of patientsPost-transplantation outcomesProportion of patientsTime of transplantContinuous-flow LVADPost-transplantation survivalHeart allocation policyNew allocation systemBaseline recipientStatus 1AHeart transplantationIschemic timeLVAD implantationTransplant listImpact of the new heart allocation policy on patients with restrictive, hypertrophic, or congenital cardiomyopathies
Chouairi F, Mullan CW, Sen S, Mori M, Fuery M, Elder RW, Lesse J, Norton K, Clark KA, Miller PE, Mulligan D, Formica R, Rogers JG, Jacoby D, Maulion C, Anwer M, Geirsson A, Desai NR, Ahmad T. Impact of the new heart allocation policy on patients with restrictive, hypertrophic, or congenital cardiomyopathies. PLOS ONE 2021, 16: e0247789. PMID: 33651802, PMCID: PMC7924739, DOI: 10.1371/journal.pone.0247789.Peer-Reviewed Original ResearchConceptsCongenital heart diseaseAllocation system changeHeart allocation systemNew heart allocation policyNew heart allocation systemTransplantation of patientsOrgan Sharing databasePost-transplantation outcomesPost-transplant survivalTime of transplantationMechanical circulatory supportRate of transplantationNumber of patientsHeart allocation policyNew allocation systemStatus 1ACardiac transplantAdult patientsSharing databaseWaitlist survivalCirculatory supportClinical benefitCongenital cardiomyopathyUnited NetworkCHD patientsCurrent status: meeting the regulatory goals of your liver transplant program.
Batra RK, Mulligan DC. Current status: meeting the regulatory goals of your liver transplant program. Current Opinion In Organ Transplantation 2021, 26: 146-151. PMID: 33650996, DOI: 10.1097/mot.0000000000000869.Peer-Reviewed Original ResearchThe demise of islet allotransplantation in the United States: A call for an urgent regulatory update
Witkowski P, Philipson L, Kaufman D, Ratner L, Abouljoud M, Bellin M, Buse J, Kandeel F, Stock P, Mulligan D, Markmann J, Kozlowski T, Andreoni K, Alejandro R, Baidal D, Hardy M, Wickrema A, Mirmira R, Fung J, Becker Y, Josephson M, Bachul P, Pyda J, Charlton M, Millis J, Gaglia J, Stratta R, Fridell J, Niederhaus S, Forbes R, Jayant K, Robertson R, Odorico J, Levy M, Harland R, Abrams P, Olaitan O, Kandaswamy R, Wellen J, Japour A, Desai C, Naziruddin B, Balamurugan A, Barth R, Ricordi C, Collaborative T. The demise of islet allotransplantation in the United States: A call for an urgent regulatory update. American Journal Of Transplantation 2021, 21: 1365-1375. PMID: 33251712, PMCID: PMC8016716, DOI: 10.1111/ajt.16397.Peer-Reviewed Original ResearchConceptsRegulatory frameworkUnited StatesIslet allotransplantationStandard-of-care procedureUS clinical practiceClinical practiceType 1 diabetes mellitusRegulatory distinctionsMinimally manipulated tissuesInvestigation proceduresRegulatory updatesClinical trialsBiological drugsDecades of progressPatientsAllotransplantationIslet transplantationTransplantationIsletsHuman isletsRegulationDrugHuman cellsImminent demiseState
2018
American Society for Reproductive Medicine position statement on uterus transplantation: a committee opinion
Allyse M, Amer H, Coutifaris C, Falcone T, Famuyide A, Flyckt R, Gargiulo A, Heimbach J, Johannesson L, Jowsey-Gregoire S, Khan Z, Langstraat C, Levin S, McDiarmid S, Miller C, Mulligan D, O'Neill K, Penzias A, Pfeifer S, Porrett P, Quintini C, Reindollar R, Rosen C, Silasi D, Stewart E, Testa G, Tzakis A, Tullius S, Penzias A, Bendikson K, Falcone T, Gitlin S, Gracia C, Hansen K, Jindal S, Kalra S, Mersereau J, Odem R, Rebar R, Reindollar R, Rosen M, Sandlow J, Schlegel P, Stovall D. American Society for Reproductive Medicine position statement on uterus transplantation: a committee opinion. Fertility And Sterility 2018, 110: 605-610. PMID: 30196945, DOI: 10.1016/j.fertnstert.2018.06.017.Peer-Reviewed Original ResearchConceptsUterus transplantationAbsolute uterus factor infertilitySuccessful uterus transplantationSuccessful medical treatmentAmerican SocietyPatient advocacy groupsTransplanted uterusFactor infertilityMedical treatmentHealth professionalsSuccessful birthTransplantationCommittee OpinionReproductive medicinePosition statementFirst childRecent media reportsBirthAdvocacy groupsReportScientific reportsInfertilityUterus
2016
Predicting Outcomes on the Liver Transplant Waiting List in the United States
Hart A, Schladt DP, Zeglin J, Pyke J, Kim WR, Lake JR, Roberts JP, Hirose R, Mulligan DC, Kasiske BL, Snyder JJ, Israni AK. Predicting Outcomes on the Liver Transplant Waiting List in the United States. Transplantation 2016, 100: 2153-2159. PMID: 27490411, PMCID: PMC5369025, DOI: 10.1097/tp.0000000000001384.Peer-Reviewed Original ResearchConceptsDonation service areaLiver transplantWaiting listEnd-stage liver disease (MELD) scoreLiver transplant waiting listTransplant Recipients databaseLiver Disease scoreMELD exception pointsTransplant waiting listAvailability of organsTransplant probabilityRecipients databasePatient characteristicsScientific RegistryTransplant programsUS adultsDisease scorePredicting OutcomeException pointsTransplantBlood typeOutcomesOngoing disparitiesCorresponding percentilesOnline calculatorPerioperative outcomes of coronary artery bypass graft in renal transplant recipients in the United States: results from the Nationwide Inpatient Sample
Tooley JE, Bohl DD, Kulkarni S, Rodriguez‐Davalos M, Mangi A, Mulligan DC, Yoo PS. Perioperative outcomes of coronary artery bypass graft in renal transplant recipients in the United States: results from the Nationwide Inpatient Sample. Clinical Transplantation 2016, 30: 1258-1263. PMID: 27440000, DOI: 10.1111/ctr.12816.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overCoronary Artery BypassCoronary Artery DiseaseDatabases, FactualFemaleHospital CostsHospital MortalityHumansKidney TransplantationLength of StayLinear ModelsLogistic ModelsMaleMiddle AgedPostoperative ComplicationsRenal DialysisRenal Insufficiency, ChronicRetrospective StudiesTreatment OutcomeUnited StatesYoung AdultConceptsChronic kidney diseaseNationwide Inpatient SampleLength of stayCKD patientsCABG surgeryHospital mortalityPerioperative outcomesInpatient SampleCardiovascular diseaseCoronary artery bypass graftKidney transplant patientsRenal transplant recipientsRetrospective cohort studyArtery bypass graftRate of complicationsTotal hospital chargesBetter perioperative outcomesCause of morbidityCost of hospitalizationNumber one causeGraft lossPerioperative complicationsTransplant patientsTransplant recipientsCohort study
2015
Early Changes in Liver Distribution Following Implementation of Share 35
Massie AB, Chow EK, Wickliffe CE, Luo X, Gentry SE, Mulligan DC, Segev DL. Early Changes in Liver Distribution Following Implementation of Share 35. American Journal Of Transplantation 2015, 15: 659-667. PMID: 25693474, PMCID: PMC6116537, DOI: 10.1111/ajt.13099.Peer-Reviewed Original ResearchConceptsDeceased donor liver transplantBaseline MELDShare 35Waitlist mortalityLiver distributionEarly posttransplant outcomesLower waitlist mortalityOdds of discardHandful of centersPosttransplant lengthLiver transplantPosttransplant mortalityPosttransplant outcomesEquivalent time periodMore transplantsEarly changesMELDMortalityPatientsTransplantMonthsEvidence of changes
2014
Written informed consent for living liver donor evaluation: Compliance with centers for medicare and medicaid services and organ procurement and transplantation network guidelines and alibi offers
Thiessen C, Kim YA, Yoo PS, Rodriguez‐Davalos M, Mulligan D, Kulkarni S. Written informed consent for living liver donor evaluation: Compliance with centers for medicare and medicaid services and organ procurement and transplantation network guidelines and alibi offers. Liver Transplantation 2014, 20: 416-424. PMID: 24415564, DOI: 10.1002/lt.23822.Peer-Reviewed Original Research
2011
A randomized, multicenter study comparing steroid‐free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C
Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, Pomfret EA, Vargas HE, Brown R, Eckhoff D, Pruett TL, Roberts J, Mulligan DC, Charlton MR, Heffron TG, Ham JM, Douglas DD, Sher L, Baliga PK, Kinkhabwala M, Koneru B, Abecassis M, Millis M, Jennings LW, Fasola CG. A randomized, multicenter study comparing steroid‐free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transplantation 2011, 17: 1394-1403. PMID: 21850690, DOI: 10.1002/lt.22417.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAntibodies, Monoclonal, HumanizedAntiviral AgentsBiopsyChi-Square DistributionDaclizumabDrug Therapy, CombinationFemaleGraft RejectionHepacivirusHepatitis C, ChronicHumansImmunoglobulin GImmunosuppressive AgentsKaplan-Meier EstimateLiver FailureLiver TransplantationMaleMiddle AgedMycophenolic AcidProportional Hazards ModelsProspective StudiesRecurrenceRisk AssessmentRisk FactorsRNA, ViralSurvival RateTacrolimusTime FactorsTreatment OutcomeUnited StatesConceptsAcute cellular rejectionSteroid-free immunosuppressionLiver transplant recipientsHCV recurrenceMycophenolate mofetilTransplant recipientsHCV RNA-positive subjectsHepatitis C virus infectionSevere HCV recurrenceSteroid-free groupC virus infectionChronic hepatitis CGraft survival ratesProportion of patientsLiver biopsy samplesCellular rejectionChronic HCVStandard immunosuppressionSteroid sparingHepatitis CLess diabetesMulticenter trialMulticenter studyPatient survivalArm 1Laparoscopic Distal Pancreatectomy
Mekeel KL, Moss AA, Reddy KS, Mulligan DC, Harold KL. Laparoscopic Distal Pancreatectomy. Surgical Laparoscopy Endoscopy & Percutaneous Techniques 2011, 21: 362-365. PMID: 22002275, DOI: 10.1097/sle.0b013e31822e0ea8.Peer-Reviewed Original ResearchConceptsLaparoscopic distal pancreatectomyDistal pancreatectomyLaparoscopic pancreatectomySpleen-preserving groupSpleen-preserving pancreatectomyLess blood lossShorter operative timeConcomitant splenectomyInfectious complicationsSplenectomy groupSurgical complicationsBlood lossPancreatic leakSplenic preservationOperative timeRetrospective reviewHand assistanceSplenic vesselsPancreatectomyAnatomic concernsPatientsDelicate dissectionComplicationsSplenectomySpleen
2010
Hepatic epithelioid haemangioendothelioma: is transplantation the only treatment option?
Grotz TE, Nagorney D, Donohue J, Que F, Kendrick M, Farnell M, Harmsen S, Mulligan D, Nguyen J, Rosen C, Reid-Lombardo K. Hepatic epithelioid haemangioendothelioma: is transplantation the only treatment option? Hepato Pancreato Biliary 2010, 12: 546-553. PMID: 20887322, PMCID: PMC2997660, DOI: 10.1111/j.1477-2574.2010.00213.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsChi-Square DistributionDisease-Free SurvivalFemaleHemangioendothelioma, EpithelioidHepatectomyHumansKaplan-Meier EstimateLiver NeoplasmsLiver TransplantationMaleMiddle AgedPalliative CareProportional Hazards ModelsRetrospective StudiesRisk AssessmentRisk FactorsSurvival RateTime FactorsTreatment OutcomeUnited StatesYoung AdultConceptsHepatic epithelioid haemangioendotheliomaOrthotopic liver transplantationDisease-free survivalLiver resectionOverall survivalPrognostic factorsFavorable prognostic factorUnfavourable prognostic factorOnly treatment optionUnpredictable clinical behaviorRare vascular neoplasmResectable diseaseUnresectable diseaseEpithelioid haemangioendotheliomaLiver transplantationFavorable OSFemale predominanceMedian ageSurgical treatmentMultifocal diseaseRetrospective reviewTreatment optionsLarge tumorsClinical behaviorMayo Clinic
2009
ASTS Recommended Practice Guidelines for Controlled Donation after Cardiac Death Organ Procurement and Transplantation
Reich DJ, Mulligan DC, Abt PL, Pruett TL, Abecassis MM, D’Alessandro A, Pomfret EA, Freeman RB, Markmann JF, Hanto DW, Matas AJ, Roberts JP, Merion RM, Klintmalm GB, Committee T. ASTS Recommended Practice Guidelines for Controlled Donation after Cardiac Death Organ Procurement and Transplantation. American Journal Of Transplantation 2009, 9: 2004-2011. PMID: 19624569, DOI: 10.1111/j.1600-6143.2009.02739.x.Peer-Reviewed Original ResearchConceptsOrgan donationFavorable posttransplant outcomesOrgan acceptance criteriaOrgan procurement organizationsBrain death criteriaBiliary issuesDCD kidneysPancreas transplantationVentilatory supportPosttransplant outcomesCardiac deathTransplant centersIschemia timeDCD protocolsHopeless prognosisMachine perfusionBrain deathTransplant surgeonsOperative techniqueOrgan transplantationPractice guidelinesBest practice guidelinesOrgan procurementDonor characteristicsTransplantation
2007
Coccidioidomycosis in healthy persons evaluated for liver or kidney donation
Blair JE, Mulligan DC. Coccidioidomycosis in healthy persons evaluated for liver or kidney donation. Transplant Infectious Disease 2007, 9: 78-82. PMID: 17313480, DOI: 10.1111/j.1399-3062.2006.00179.x.Peer-Reviewed Original ResearchConceptsDonor-derived coccidioidomycosisKidney donationTransplant recipientsHealthy personsDonor candidatesOrgan donor candidatesRisk of transmissionProphylaxis protocolLiver donationFourth patientCoccidioidal antibodiesPossible liverCoccidioidomycosisFungal infectionsCoccidioides speciesRecipientsFurther studiesPatientsLiverRiskDonationProphylaxisUnique challengesInfectionPrevalence
2006
Reduced Priority MELD Score for Hepatocellular Carcinoma Does Not Adversely Impact Candidate Survival Awaiting Liver Transplantation
Sharma P, Harper AM, Hernandez JL, Heffron T, Mulligan DC, Wiesner RH, Balan V. Reduced Priority MELD Score for Hepatocellular Carcinoma Does Not Adversely Impact Candidate Survival Awaiting Liver Transplantation. American Journal Of Transplantation 2006, 6: 1957-1962. PMID: 16771808, DOI: 10.1111/j.1600-6143.2006.01411.x.Peer-Reviewed Original ResearchConceptsDeceased donor liver transplantationHepatocellular carcinomaHCC candidatesCandidate survivalLiver transplantationMELD scoreStage T1Waiting listEnd-stage liver diseaseDonor liver transplantationT2 hepatocellular carcinomaOrgan allocation policyUNOS databaseLiver transplantLiver diseasePatient survivalUnited NetworkHCC patientsIncidence rateOrgan SharingSurvivalTransplantationCarcinomaDropout rateTime period
2004
Liver transplantation for hepatocellular carcinoma: The MELD impact
Sharma P, Balan V, Hernandez JL, Harper AM, Edwards EB, Rodriguez‐Luna H, Byrne T, Vargas HE, Mulligan D, Rakela J, Wiesner RH. Liver transplantation for hepatocellular carcinoma: The MELD impact. Liver Transplantation 2004, 10: 36-41. PMID: 14755775, DOI: 10.1002/lt.20012.Peer-Reviewed Original ResearchConceptsDeceased donor liver transplantationNew allocation policyHCC candidatesPerson yearsIncidence rateHepatocellular carcinomaLiver transplantationUNOS databaseEnd-stage liver diseaseT2 hepatocellular carcinomaDonor liver transplantationDropout rateDate of implementationHepatic decompensationNew MELDClinical deteriorationMELD scoreLiver diseaseStage T1United NetworkOrgan SharingWaiting listSurvivalTransplantationCarcinoma
2003
Recent Advances in Liver Transplantation
Wiesner RH, Rakela J, Ishitani MB, Mulligan DC, Spivey JR, Steers JL, Krom RA. Recent Advances in Liver Transplantation. Mayo Clinic Proceedings 2003, 78: 197-210. PMID: 12583530, DOI: 10.4065/78.2.197.Peer-Reviewed Original ResearchConceptsLiver transplantationHepatitis CEnd-stage liver disease (MELD) allocation systemRecurrent hepatitis C.Acute cellular rejectionDonor liver transplantationRecurrent hepatitis CDeath of patientsLong-term survivalLiver allocation policyQuality of lifeCellular rejectionChronic rejectionDomino transplantationImmunosuppressive regimensMetabolic complicationsRecurrent diseaseHepatitis C.Marginal donorsProlong survivalUnited NetworkHepatic support systemDonor poolEffective therapyDonor organs
1998
Cost analysis of four strategies for prevention of CMV infection in liver transplant recipients
Post AB, Mulligan DC, Bush W. Cost analysis of four strategies for prevention of CMV infection in liver transplant recipients. Transplantation Proceedings 1998, 30: 2102-2103. PMID: 9723406, DOI: 10.1016/s0041-1345(98)00553-3.Peer-Reviewed Original Research